Rapport Therapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|
| Revenue | $0 | $20.0M | $0 | $0 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $51.4M | $32.7M | $22.7M | $19.6M |
| SG&A Expense | $9.4M | $11.5M | $6.8M | $7.5M |
| Operating Income | $-60.8M | $-24.2M | $-29.5M | $-27.1M |
| Operating Margin | — | -121.1% | — | — |
| Interest Expense | — | — | — | — |
| Pretax Income | — | — | — | — |
| Income Tax Expense | — | — | — | — |
| Net Income | $-56.6M | $-19.9M | $-26.7M | $-24.1M |
| Net Margin | — | -99.3% | — | — |
| EPS (Basic) | $-1.19 | $-0.42 | $-0.75 | $-0.68 |
| EPS (Diluted) | $-1.19 | $-0.42 | $-0.75 | $-0.68 |
| Shares Outstanding (Basic) | 47.5M | 47.2M | 35.4M | 35.3M |
| Shares Outstanding (Diluted) | 47.5M | 47.2M | 35.4M | 35.3M |
| Dividends Per Share | — | — | — | — |